Table 2.
Results of observational studies of an ALK inhibitor after initial ALK inhibitor – median OS
| Reference | Median OS from initiation of second ALK inhibitor, months | Median OS from initiation of first ALK inhibitor (ie, OS of ALK sequence), months | Median OS from diagnosis of metastatic disease, months |
|---|---|---|---|
| Ceritinib after initial crizotinib | |||
| Bendaly et al81 | NR | NR | NR |
| Bendaly et al80 | 15.5 | NR | NR |
| Gainor et al82 | NR | 30.3a | 49.4 |
| Kayaniyil et al48 | 20.4 | NR | 51.0 |
| Alectinib after initial crizotinib | |||
| Ito et al44 | NR | Not reachedb | NR |
| Watanabe et al84 | NR | 48.6 | 51.1 |
| Asao et al46 | NR | NR | NR |
| Yoshida et al57 | NR | NR | NR |
| Any second-generation ALK inhibitor after crizotinib | |||
| Chiari et al45 | 22 | 40 | NR |
| Roeper et al83 | NR | Not reachedc | NR |
| Nosaki et al47 | NR | 63.75 | NR |
| Cadranel et al50 | NR | Not reachedd | NR |
| Duruisseaux et al54 | NR | Not reachede | 89.6 |
| Second-generation ALK inhibitor after second generation | |||
| Nosaki et al47 | NR | Not reachedf | NR |
Notes:
a
From initiation of crizotinib in subset of patients previously treated with chemotherapy.
b
Median duration of follow-up: 21.3 months.
c
Median duration of follow-up: not reported.
d
Median duration of follow-up: 21.4 months.
e
Median duration of follow-up: 44.4 months.
f
Median duration of follow-up: not reported.
Abbreviations: NR, not reported; OS, overall survival.